OrthoPediatrics AI Stock Analysis
Want to see KIDS full AI Analyst Report?
OrthoPediatrics (KIDS) AI Stock Analysis
OrthoPediatrics
(NASDAQ:KIDS)
The score is driven primarily by improving fundamentals (strong revenue growth, high gross margins, and a recent move to positive TTM operating/free cash flow) and a very constructive earnings update with raised revenue guidance and reiterated EBITDA/FCF targets. Offsetting these positives are the still-lossmaking profile (negative net margin and negative P/E) and technically overbought momentum indicators that increase near-term pullback risk.
OrthoPediatrics (KIDS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $822.48M
- Dividend Yield
- ―
- Average Volume (3M)
- 281.22K
- Price to Earnings (P/E)
- -22.0
- Beta (1Y)
- 0.70
- Revenue Growth
- 16.15%
- EPS Growth
- 27.21%
- Country
- US
- Employees
- 602
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
OrthoPediatrics Business Overview & Revenue Model
Company Description
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children af...
How the Company Makes Money
OrthoPediatrics primarily makes money by selling pediatric-focused orthopedic implants and the associated surgical instruments/sets used to implant them. Revenue is generated when hospitals and ambulatory surgery centers purchase the company’s steril...
OrthoPediatrics Earnings Call Summary
The call was strongly positive, with record revenue, 19% quarterly growth, a raised full-year revenue outlook, record adjusted EBITDA, positive quarterly free cash flow, strong demand across core businesses, and substantial progress in product launches and clinic expansion. The main challenges were that many super-cycle products remain in limited launch, eLLi commercialization is largely a 2028-2029 opportunity, year-to-date free cash flow remains negative, and operating expenses and commissions increased. Overall, the breadth and magnitude of the reported growth and management's confidence outweighed the timing and investment-related challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company raised full year 2026 revenue guidance to the range of $270 million to $273 million, representing growth of 14% to 16%, reiterated adjusted EBITDA guidance of approximately $25 million, and continues to expect to deploy approximately $10 million in sets and achieve free cash flow break-even or better in 2026, with free cash flow positive in 2027 and beyond; year to date free cash flow was about $6 million of usage, requiring $6 million of positive free cash flow in the fourth quarter to reach breakeven or better for the year, and fourth-quarter gross margin was projected at 73%.
OrthoPediatrics Financial Statement Overview
Summary
Strong multi-year revenue growth with consistently high gross margins (low-to-mid 70s) is a clear positive, and TTM shows an inflection to positive operating cash flow ($12.5M) and positive free cash flow ($3.2M). However, profitability remains the key weakness (negative EBIT and meaningfully negative TTM net margin of -12.8%), and cash-flow consistency is not yet proven after multiple years of negative operating cash flow.
Income Statement
46NeutralBalance Sheet
63PositiveCash Flow
44Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 264.14M | 236.35M | 204.73M | 148.73M | 122.29M | 98.05M |
| Gross Profit | 194.84M | 172.66M | 148.60M | 111.25M | 90.66M | 73.40M |
| EBITDA | 2.43M | -12.07M | -20.23M | -8.38M | -8.69M | -7.19M |
| Net Income | -33.88M | -39.65M | -37.82M | -20.97M | 1.26M | -16.26M |
Balance Sheet | ||||||
| Total Assets | 509.09M | 508.63M | 473.21M | 438.75M | 427.73M | 308.40M |
| Cash, Cash Equivalents and Short-Term Investments | 44.23M | 60.85M | 68.83M | 80.31M | 118.29M | 54.91M |
| Total Debt | 98.36M | 99.99M | 80.90M | 10.06M | 907.00K | 28.51M |
| Total Liabilities | 169.74M | 162.03M | 118.64M | 61.72M | 49.08M | 83.03M |
| Stockholders Equity | 339.35M | 346.60M | 354.57M | 377.02M | 378.65M | 225.37M |
Cash Flow | ||||||
| Free Cash Flow | 3.18M | -15.96M | -41.31M | -46.03M | -31.80M | -29.07M |
| Operating Cash Flow | 12.49M | -4.85M | -27.05M | -27.05M | -21.77M | -13.06M |
| Investing Cash Flow | -10.20M | -43.63M | -13.16M | 41.68M | -113.37M | -7.41M |
| Financing Cash Flow | -3.30M | 23.98M | 53.13M | 7.30M | 135.97M | 6,000 |
OrthoPediatrics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KIDS, the sentiment is Positive. The current price of 31.50 is above the 20-day moving average (MA) of 29.72, above the 50-day MA of 25.25, and above the 200-day MA of 20.35, indicating a bullish trend. The MACD of 2.41 indicates Positive momentum. The RSI at 60.89 is Neutral, neither overbought nor oversold. The STOCH value of 38.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KIDS.
OrthoPediatrics Risk Analysis
OrthoPediatrics disclosed 79 risk factors in its most recent earnings report. OrthoPediatrics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksOrthoPediatrics Peers Comparison
Overall Rating
GMED73Outperform
ZBH69Neutral
KIDS61Neutral
ENOV58Neutral
ATEC50Neutral
OFIX44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $9.34B | 17.03 | 11.82% | ― | 13.35% | 32.22% | |
| 69Neutral | $19.19B | 25.65 | 6.05% | 0.95% | 6.98% | -2.22% | |
| 61Neutral | $822.48M | -22.04 | -9.91% | ― | 16.15% | 27.21% | |
| 58Neutral | $1.61B | -2.98 | -35.53% | ― | 3.28% | 62.02% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $1.05B | -12.11 | -547.17% | ― | 15.34% | 46.31% | |
| 44Neutral | $277.17M | -6.14 | -10.32% | ― | 2.12% | 63.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KIDS | Orthopediatrics Corp | 31.50 | 14.88 | 89.53% | |
| ATEC | Alphatec | 6.78 | -12.84 | -65.44% | |
| ENOV | Enovis Corporation | 27.92 | 0.75 | 2.76% | |
| OFIX | Orthofix Medical Inc. | 6.80 | -7.66 | -52.97% | |
| ZBH | Zimmer Biomet Holdings | 101.41 | 12.91 | 14.58% | |
| GMED | Globus Medical | 70.50 | -13.32 | -15.89% |
OrthoPediatrics Corporate Events
OrthoPediatrics Highlights Pediatric-Focused Strategy in Investor Deck
PositiveOrthoPediatrics Corp.’s executive team has scheduled upcoming presentations to investors and analysts in which they will use a 2026 investor deck outlining their pediatric-focused business model and financial metrics. The presentation reiterates the...
OrthoPediatrics Highlights Growth in 2026 Investor Presentations
PositiveOrthoPediatrics’ executive officers plan upcoming presentations to investors and analysts using a new 2026 investor deck that highlights the company’s pediatric-only focus and outlines its use of non-GAAP metrics such as free cash flow, adjusted dilu...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
